Takeda’s Entyvio, Janssen’s Stelara, and AbbVie’s Humira leave the most on the table when first-line biologic or small molecule agents...
A high percentage of GA patients are either being seen for the first time, or not returning for follow-up visits...
Despite highly favorable perceptions of the first approved treatment, dermatologists’ desire increased support from Eli Lilly sales representatives EXTON, Pa.,...
The Philadelphia100® Forum and the Philadelphia Business Journal recognize Spherix Global Insights among this year’s top companies in the Greater...
Referrals from primary care physicians to rheumatologists are being delayed due to several factors EXTON, Pa., November 10, 2022 /PRNewswire/...
While Eylea holds the second-place position, newcomer Vabysmo (Genentech) has already captured a small piece of the market and is...
Expanded systemic lupus erythematosus (SLE) research in Europe reveals UK physicians perceive a higher unmet need and difficulty in treating...
Independently funded research on the role of primary care physicians in CKD care, SGLT2 inhibitors and advancing care for IgA...
Despite satisfaction among gastroenterologists and allergists who have trialed the drug, high patient out-of-pocket costs and reimbursement hassles could hamper...
IL-23 inhibitors and AbbVie’s Rinvoq are projected to have the largest growth in the coming months EXTON, Pa., October 13,...
Coherus’ new ranibizumab biosimilar, Cimerli, and the anticipated 8mg aflibercept formulation are predicted to further shake up the DME landscape...
Rinvoq and Skyrizi are making waves in ulcerative colitis and Crohn’s disease; is Takeda’s Entyvio in the hot seat? EXTON,...
